No Data
BioXcel Therapeutics(BTAI.US) 10% Shareholder Sells US$405.14K in Common Stock
$BioXcel Therapeutics(BTAI.US)$ 10% Shareholder Mehta Vimal sold 252.03K shares of common stock on Jun 4, 5, 2024 at an average price of $1.6075 for a total value of $405.14K. This transaction involve
Form 144 | BioXcel Therapeutics(BTAI.US) 10% Stockholder Proposes to Sell 378.04K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 4, $BioXcel Therapeutics(BTAI.US)$ 10% Stockholder BioXcel LLC intends to sell 252.03K shares of its common stock on Jun 4, with a total market value of approximately $378.
Analysts' Opinions Are Mixed on These Healthcare Stocks: Teleflex (TFX), Bioxcel Therapeutics (BTAI) and Prothena (PRTA)
Hold Rating on Bioxcel Therapeutics Amid Growth Potential and Financial Uncertainties
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript
Bullish Outlook: Bioxcel Therapeutics' Revenue Surge and Promising Clinical Trials Fuel Buy Rating